Table 2.
Comparison of studies on radiographic progression in patients with ankylosing spondylitis.
| Author, year | Study groups | Number of Participants | Study Length | Baseline mSASSS, mean (SD) | Smoking status (%) | Male (%) | HLA-B27 positivity (%) | mSASSS change, mean (SD) |
|---|---|---|---|---|---|---|---|---|
| NSAIDs [Randomized controlled Trials] | ||||||||
| Wanders, 2005 (14) | Continuous celecoxib | 76 | 2 years | 7.9 (14.7) | NR | 66 | 88 | 0.4 (1.7) |
| On-demand celecoxib | 74 | 2 years | 9.3 (15.2) | NR | 70 | 88 | 1.5 (2.5) | |
| Sieper, 2015 (15) | Continuous diclofenac | 62 | 2 years | 10.9 (15.5) | 59* | 71.0 | 88.7 | 1.3 (0.7–1.9) |
| On-demand diclofenac | 60 | 2 years | 16.4 (18.2) | 33* | 66.7 | 91.7 | 0.8 (0.2–1.4) | |
| TNFi [Retrospective analyses of clinical trials/long-term extension of clinical trial data] | ||||||||
| Baraliakos, 2005 (37) | Infliximab | 41 | 2 years | 12.1 | NR | 63 | 90 | 0.4(2.7) |
| GESPIC cohort | 41 | 2 years | 5.9 | NR | 71 | 85 | 0.7(2.8) | |
| van der Heijde, 2008 (19) | Infliximab | 201 | 2 years | 17.7 (17.9) | NR | 78.1 | 86.5 | 0.9 (2.6) |
| OASIS | 192 | 2 years | 15.8 (18.1) | NR | 67.7 | 84.4 | 1.0 (3.2) | |
| van der Heijde, 2008 (38) | Etanercept | 257 | 2 years | 16 (18.3) | NR | 75.5 | 78.2 | 0.91 (2.45) |
| OASIS | 175 | 2 years | 14 (17.6) | NR | 69.1 | 71.1 | 0.95 (3.18) | |
| van der Heijde, 2009 (20) | Adalimumab | 307 | 2 years | 19.8 (19.3) | NR | 76.5 | NR | 0.8 (2.6) |
| OASIS | 169 | 2 years | 15.8 (17.6) | NR | 69.2 | NR | 0.9 (3.3) | |
| Braun, 2014 (39) | Placebo -> Golimumab 50mg | 66 | 208 weeks | 16.1 (18.7) | NR | NR | NR | 2.1 (5.2) |
| Golimumab 50mg | 111 | 208 weeks | 11.7 (16.4) | NR | NR | NR | 1.3 (4.1) | |
| Golimumab 100mg | 112 | 208 weeks | 13.5 (18.9) | NR | NR | NR | 2.0 (5.6) | |
| IL-17A inhibitor [Retrospective analyses of clinical trials/long-term extension of clinical trial data] | ||||||||
| Braun, 2018 (40) | Secukinumab 75mg | 61 | 208 weeks | 10.7 (17.82) | 39.3 | 87.0 | NR | 1.6 (5.67) |
| Secukinumab 75mg -> 150mg | 23 | 208 weeks | 34.8 | 70.5 | NR | 1.8 (4.32) | ||
| Secukinumab 150mg | 71 | 208 weeks | 8.6 (16.23) | 29.6 | 63.4 | NR | 1.2 (3.91) | |
| Braun, 2019 (23) | Secukinumab | 168 | 2 years | NR | 25 | 73.2 | 82.9 | 60.7% * |
| ENRADAS cohort | 69 | 2 years | NR | 44.9 | 66.7 | 88.4 | 52.2% * p = 0.2430 |
|
NSAID: non-steroidal anti-inflammatory drugs; TNFi: tumor necrosis factor inhibitor; IL-17A: interleukin-17A; GESPIC: German Spondyloarthritis Inception Cohort; OASIS: Outcomes in Ankylosing Spondylitis International Study; ENRADAS: Effects of NSAIDs on Radiographic Damage in Ankylosing Spondylitis; SD: standard deviation; NR: not reported.
*
Proportion of patients with no radiographic progression (least squares mean change of mSASSS <= 0)